In addition, the present results support the hypothesis that low cf-mtDNA, together with low Aβ and high p-tau, constitute a distinctive CSF biomarker profile that differentiates slow AD progression from patients with other neurodegenerative diseases. The gene discussed is MAPT; the disease is Alzheimer disease.